Myriad Genetics, Inc.

Susanne Wagner

Julia Reid

Alexander Gutin

Steven Stone

Victor Abkevich

Mark Hess

Jerry Lanchbury

Dennis G Ballinger

Wei Ding

Fabiana Filigheddu

Steve Stone

Jutta Reid

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

Gene signatures for cancer prognosis

Biomarkers and methods using the biomarkers for classifying cancer in a patient (e.g., predicting the risk of cancer-specific death or cancer recurrence) are provided.

Cancer Biomarkers

Cancer biomarkers

Biomarkers and methods using the biomarkers for molecular detection and classification of disease and, particularly, molecular markers for cancer diagnosis and prognosis and methods of use thereof are provided.

Gene signatures for cancer diagnosis and prognosis

Methods of using a genetic polymorphic variation in the human beta-1 adrenergic receptor gene as a drug response marker are presented. Determining the presence or absence of the A145G genetic variation in the human beta-1 adrenergic receptor gene is useful in predicting an individual's relative response to different antihypertensive drugs; optimizing antihypertensive treatment for an individual; selecting candidate human subjects for participation in clinical trials involving antihypertensive drugs; and, predicting the relative responses among a plurality of individuals to an antihypertensive drug.

Drug response marker in beta-1 adrenergic receptor gene

Human coronary heart disease susceptibility gene (CHD1), some alleles of which are related to susceptibility to coronary heart disease. Germline mutations in the CHD1 gene and their use in the diagnosis of predisposition to coronary heart disease and to metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, obesity, diabetes and dyslipidemic hypertension. Presymptomatic therapy of individuals who carry deleterious alleles of the CHD1 gene (including gene therapy, protein replacement therapy, and administration of protein mimetics and inhibitors). The screening of drugs for dyslipidemic therapy.

Growing community of inventors

Salt Lake City, UT, United States of America

Susanne Wagner